Atlanta-A lithotripter with a broad focal spot is advantageous for accelerating stone fracture, said Robin O. Cleveland, PhD, at the AUA annual meeting here.
Pembrolizumab/axitinib efficacy in ccRCC sustained at 5-year follow-up
At a median follow-up of 67.2 months, the combination of pembrolizumab and axitinib continued to show an overall survival and progression-free survival benefit over sunitinib monotherapy in the first-line setting.
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Cabozantinib/atezolizumab does not improve PFS or OS in advanced RCC
“The addition of atezolizumab to cabozantinib did not result in improved clinical outcomes in patients with mRCC who progressed on or after prior ICI treatment,” said Toni K. Choueiri, MD.
2023 AUA highlights in benign urology
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Enfortumab vedotin/pembrolizumab combo shows safety, efficacy in metastatic urothelial carcinoma
"In EV-103 dose escalation/cohort A, the safety profile of the combination was manageable, with no new safety concerns observed at nearly 4 years of follow-up," said Shilpa Gupta, MD.
Lenvatinib/pembrolizumab efficacy in renal cell carcinoma sustained at 4-year follow-up
At a median follow-up of about 50 months, lenvatinib plus pembrolizumab maintained an overall survival benefit compared with sunitinib in patients with advanced renal cell carcinoma.
2 Clarke Drive Cranbury, NJ 08512